Search Results

A recent report has predicted that hepatitis C virus (HCV) drug sales will almost quadruple by 2013, across major markets.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 581, 2009-06-27 , pp. 10-10(1)

Publisher: Adis International

Etanercept, infliximab and adalimumab have driven the growth in the spondyloarthropathy market, which reached nearly $US2 billion

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 579, 2009-05-30 , pp. 14-14(1)

Publisher: Adis International

The Chinese non-small-cell lung cancer (NSCLC) drug market is expected to more than double by 2013

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 579, 2009-05-30 , pp. 15-15(1)

Publisher: Adis International

The market for innovative biotherapies for cancer is expected to have strong growth over the next 10 years

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 579, 2009-05-30 , pp. 15-15(1)

Publisher: Adis International

ED drug market predicted to remain firm

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 570, 2009-01-24 , pp. 10-10(1)

Publisher: Adis International

Homoeopathic medicines are subject to rigorous testing similar to that used for conventional drugs

Source: Inpharma, Volume 1, Number 1521, 2006-01-21 , pp. 3-3(1)

Publisher: Adis International

The Japanese market for anticancer therapies is likely to reach ¥415 billion in 2006

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 476, 2005-04-23 , pp. 10-10(1)

Publisher: Adis International

Treatment with methylphenidate [Ritalin] may be associated with an increased risk of cancer in children

Source: Reactions, Volume 1, Numbers 1044-1045, 2005-03-26 , pp. 5-5(1)

Publisher: Adis International

Following the release of Q4 2004 earnings, the leadership position of UCB Pharma's cetirizine [Zyrtec] as the most prescribed brandname antihistamine in new prescriptions in the US has been confirmed.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 470, 2005-01-29 , pp. 11-11(1)

Publisher: Adis International

Eurand has received final UK approval for diclofenac 75mg and 100mg modified-release capsules

Source: Inpharma, Volume 1, Number 1461, 2004-10-30 , pp. 18-18(1)

Publisher: Adis International

Ranbaxy Pharmaceuticals has announced the US launch of cephalexin [Panixine DisperDose] oral suspension in 125mg and 250mg strengths.

Source: Inpharma, Volume 1, Number 1442, 2004-06-19 , pp. 18-18(1)

Publisher: Adis International

Vardenafil [Levitra; Bayer] has been approved in Japan

Source: Inpharma, Volume 1, Number 1436, 2004-05-08 , pp. 18-18(1)

Publisher: Adis International

A new IV formulation of esomeprazole [`Nexium'; AstraZeneca] is to be launched in Sweden.

Source: Inpharma, Volume 1, Number 1403, 2003 , pp. 18-18(1)

Publisher: Adis International

The demand for anti-aging products is expected to increase by > 11% annually, to reach $US29 billion in 2007

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 424, 2003 , pp. 11-11(1)

Publisher: Adis International

Celgene to command drug sales for multiple myeloma

Source: PharmacoEconomics and Outcomes News, Volume 1, Numbers 408-409, 2003 , pp. 11-11(1)

Publisher: Adis International

Sales of single-pill combination drug therapies for type 2 diabetes mellitus

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 383, 2002 , pp. 11-11(1)

Publisher: Adis International

Federal and state action is being sought against pharmaceutical company AstraZeneca

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 376, 2002 , pp. 12-12(1)

Publisher: Adis International

Generic lisinopril to save millions in the US

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 376, 2002 , pp. 11-11(1)

Publisher: Adis International

Net sales of $US15.4 million have been announced for nesiritide [`Natrecor'] for Q1 this year.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 358, 2002 , pp. 11-11(1)

Publisher: Adis International